lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking forward to the amended complaint.
That isn't the case sorry.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173850251
not how it usually works. you don't pass plead specifics at this stage. the amount of damages is whatever the jury will award, or at least that is how I would answer that interrogatory. experts will put together their report(s) and the jury will decide. what you're suggesting…
— hoffmann6383 (@hoffmann6383) February 15, 2024
I agree entirely
You must be horrible at poker.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173850251
Posner had no obligation to show all evidence right away. This is novel law without much precedent to rely upon. It would be best to get opinion of the court, as she did, so now she can respond further as the court allows.
Cohen Milstein are aware of loss causation as an element that must be met to survive MTD. We met all other elements. They wouldn't tie up resources on contingency for a case that would be thrown out at MTD. I expect they're being strategic.
They will now provide the evidence.
👨⚖️Judge Woods Motion to Dismiss Ruling👨⚖️$NWBO
— hoffmann6383 (@hoffmann6383) February 15, 2024
The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)
On February 14, 2024 Judge Woods granted Defendants’ Motion to Dismiss (“MTD”), with leave to amend. The Order can be found here:…
Fraud cases require a high bar be met otherwise there would be shakedown artists suing companies into bankruptcy. This is all expected. I believe we will survive MTD with the amended complaint that proves loss causation.
👨⚖️Judge Woods Motion to Dismiss Ruling👨⚖️$NWBO
— hoffmann6383 (@hoffmann6383) February 15, 2024
The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)
On February 14, 2024 Judge Woods granted Defendants’ Motion to Dismiss (“MTD”), with leave to amend. The Order can be found here:…
Correct we go through this process again once Posner amends complaint.
👨⚖️Judge Woods Motion to Dismiss Ruling👨⚖️$NWBO
— hoffmann6383 (@hoffmann6383) February 15, 2024
The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.)
On February 14, 2024 Judge Woods granted Defendants’ Motion to Dismiss (“MTD”), with leave to amend. The Order can be found here:…
Loss causation must be proven or the motion to dismiss will be granted. I believe Posner will be able to prove this final element required for the case to survive the motion to dismiss. Looking forward to cured response filed in 30 days or less.
JAMA took about four months to be published. So it's reasonable to conclude we will see the Nature paper soon.
Yes, he's off his rocker. I can forgive being hungover or smoking a bad batch of herb.
Nature paper due anytime.
https://www.researchsquare.com/article/rs-3287211/v1
Good management teams often spend their time dispelling insane rumors.
I think your account was compromised. That's the only explanation for this QAnon-like insanity.
Next they will issue PR stating the sky is blue.
Navid wasn't in possession of insider information when he sold as that would be illegal. He did it for tax purposes. He still owns nearly 25M. If you don't understand these matters then get off your soapbox as you sound like a doomsday sidewalk preacher.
Insiders have not sold their shares. I suggest you review SEC filings before propagating such lunacy.
Disappointed that you're so irrational after accurately predicting KM survival curve before top line publication.
Selling shares for tax purposes isn't negative indicator as he owns nearly 25M NWBO. Many rich people often reduce their tax liability through tax loss harvesting.
10K SEC filing makes it clear. Not worth arguing because it's waste of time. Navid will likely be a billionaire so obviously he's working diligently behind the scene on behalf of Northwest Biotherapeutics.
Navid will be a billionaire @ $40. You need to get some sleep.
David owns 25M shares. You should stop amplifying short seller narratives.
Complete bullshit. David owns 25M shares.
12000 is using clean rooms
Correct, 12K with clean rooms and north of 100K with Flaskworks.
Depending on price for DCVax, 10-30B in revenue from one facility.
Placed GTC order for more shares. Be greedy when others are fearful!
Yes, I simply would rather see us in the BBC, Telegraph, Times, etc. Perhaps that will be next month on MAA approval.
Even more trustworthy. I stand corrected.
I am huge promoter of DCVax but come on BNN are not journalists nor any publication worth touting.
Glad NJ firefighters like our product but they have zero insight into King Charles.
https://en.m.wikipedia.org/wiki/Breaking_News_Network
March could be when we get MAA approval. MHRA knows much about DCVax given Specials and PIM designation. I do not think outside experts will need to be consulted at CHM given the recent MIA and PIP approval as well. I could be wrong but given the rigorous attention Northwest gave to the MAA, combined with regulatory familiarity, I think the March prediction has a good probability of being correct.
We may get approval in less than 80 days without any CHM meeting.
I agree RRH that creating the GMP Flaskworks device should be done quickly as will validation runs at Advent. The company have already done validation runs with the experimental Flaskworks device to determine it actually works per the milestones.
We are likely simply creating GMP device from vendor with experience and certification to be of GMP quality. This should be routine without risk assuming we picked a good vendor and materials for making the devices are readily available. I do not really think the materials are any different from our development-stage Flaskworks devices as introducing such variables could fundamentally change how it performs.
I think of this as OEM vs OEE car parts as OEM includes the vendor stamp of approval but OEE are essentially the same part, made with same inputs often by same manufacturer, minus the car vendor logo.
We likely ordered them weeks ago before this PR was issued. This should all be completed quickly in my estimation as the difficult steps with Flaskworks are now done.
Per ASCO presentation 12K a year is max capacity of current clean room GMP process not Flaskworks. So many more than 12K patients a year with Flaskworks will be treated at a small 90K square foot facility.
In my opinion, given the size of the machines, Sawston should be able to treat north of 250K patients a year assuming staffing levels can be met to operate Flaskworks at that scale.
I don't think that will be an issue given the global surplus of postdocs working at Starbucks.
This is why many say we are a 100B company.
Hence why Marnix spent so much time developing assays. They only need to prove same vaccine from same patient tumor including methods like proteomics.
DCVax has not failed a trial while targets all antigens and neoantigens. It makes ADCs like Trodelvy an inferior technology as flipper astutely illuminated.
Excellent, thank you!
Trodelvy, for reference, is an ADC while it's already had trial failures. Gilead paid 21B for Trodelvy!
https://www.fiercepharma.com/pharma/gileads-adc-trodelvy-fails-nsclc-study-sending-stocks-crashing
You should have sold it then bought more shares at these depressed prices.
I believe we will be approved in phase 1 assessment yes which means this will not take 150 days.
The reasons why this could occur:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173757465
MAA submitted weeks ago with 150 day timeline that could easily be concluded in under 80. NICE appraisal likely underway as they can begin that process if MAA will be submitted during their evaluation. Do you think the UK wants to sit on this revolutionary treatment when they lost an MP to the horrible disease not long ago? It has been a matter of priority for them politically as well as a public health matter while as you know our management team has testified before MPs on DCVax. The decision makers have known about DCVax for years given Specials, PIM, while PIP, which includes gliomas, was approved on expedited basis! The facts bring nothing but rational exuberance!